Related Experiment Video

Updated: Jun 14, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Emerging role of microRNAs in prostate cancer: implications for personalized medicine

Paolo Gandellini1, Marco Folini, Nadia Zaffaroni

  • 1Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

Discovery Medicine
|March 31, 2010
PubMed

Insights

MicroRNAs (miRNAs) show altered expression in prostate cancer, potentially distinguishing tumors and predicting recurrence. Further research into these small non-coding RNAs could lead to new diagnostic biomarkers and therapeutic targets for cancer management.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression.
  • Dysregulated miRNA expression is implicated in the pathogenesis of various human tumors, including cancer.
  • Prostate cancer research has begun exploring the role of miRNAs, with limited studies available.

Purpose of the Study:

  • To investigate the role of microRNAs in prostate cancer development and progression.
  • To explore the potential of miRNAs as diagnostic and prognostic markers in prostate cancer.
  • To assess the feasibility of miRNA-based therapies for prostate cancer management.

Main Methods:

  • Analysis of miRNA expression profiles in prostate cancer specimens.
  • Correlation of miRNA expression with tumor characteristics, such as androgen dependence.
  • Investigation of specific miRNA functions in prostate cancer experimental models.

Main Results:

  • MiRNA expression profiles can differentiate between cancerous and non-neoplastic prostate tissues.
  • Specific miRNAs may classify tumors based on androgen dependence and predict recurrence after surgery.
  • Functional studies are exploring the therapeutic potential of dysregulated miRNAs in prostate cancer.

Conclusions:

  • MicroRNAs are promising novel biomarkers for prostate cancer diagnosis and prognosis.
  • Further understanding of miRNA function and targets is crucial for developing miRNA-based therapies.
  • MiRNAs represent potential intervention tools for managing prostate cancer.

More Related Videos

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...